OCTAPHARMA

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1983-01-01

Employees: -

Market Cap: -

Website: https://www.octapharma.com/

Clinical Trials

Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency

Phase 3

Completed

Conditions: Congenital Fibrinogen Deficiency

Interventions: Biological: Octafibrin

First Posted Date: 2015-04-03

Last Posted Date: 2021-01-15

Lead Sponsor: Octapharma

Target Recruit Count: 15

Registration Number: NCT02408484

Locations: 🇮🇳
St. John's Medical College Hospital, Bangalore, India
🇮🇳
S.S Institute of Medical Science and Research Center, Davangere, India
🇮🇷
Nemazee Hospital Shiraz University of Medical Sciences, Shiraz, Iran, Islamic Republic of

and more 1 locations

Non-Interventional Study on the Tolerability and Efficacy of IVIG

Completed

Conditions: Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

Interventions: Biological: Octagam IVIG 5% or 10%
Biological: Panzyga

First Posted Date: 2014-11-27

Last Posted Date: 2021-06-29

Lead Sponsor: Octapharma

Target Recruit Count: 344

Registration Number: NCT02303093

Locations: 🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
🇪🇸
Octapharma Research Location, Madrid, Spain
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada

and more 5 locations

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Phase 3

Completed

Conditions: Congenital Fibrinogen Deficiency

Interventions: Drug: Octafibrin

First Posted Date: 2014-10-17

Last Posted Date: 2021-01-15

Lead Sponsor: Octapharma

Target Recruit Count: 25

Registration Number: NCT02267226

Locations: 🇧🇬
Dept of Clinical Hematology for Hemorrhagic Diatheses and Anaemia, SHAT "Joan Pavel", Sofia, Bulgaria
🇮🇳
St. John's Medical College Hospital, Bangalore, India
🇮🇳
Dept of Hematology, Christian Medical College, Vellore, India

and more 9 locations

Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A

Phase 3

Completed

Conditions: Severe Haemophilia A

Interventions: Biological: Human cl rhFVIII

First Posted Date: 2014-10-06

Last Posted Date: 2021-01-19

Lead Sponsor: Octapharma

Target Recruit Count: 58

Registration Number: NCT02256917

Locations: 🇲🇰
PHI Institute of Transfusion Medicine of Republic of Macedonia, Skopje, North Macedonia
🇯🇵
Ogikubo Hospital, Tokyo, Japan
🇨🇦
McMaster University, Hamilton, Ontario, Canada

and more 17 locations

Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps

Phase 4

Completed

Conditions: Primary Immunodeficiency (PID)

Interventions: Biological: Gammanorm

First Posted Date: 2014-07-03

Last Posted Date: 2018-09-05

Lead Sponsor: Octapharma

Target Recruit Count: 31

Registration Number: NCT02180763

Locations: 🇫🇷
University Hospital of Lille, Lille, France
🇫🇷
Clinique Mutualiste, Lyon, France
🇫🇷
University Hospital of Toulouse, Toulouse, France

and more 5 locations

Octaplas Pediatric Plasma Replacement Trial

Phase 4

Completed

Conditions: Coagulopathy
Cardiac Surgery
Liver Surgery
Liver Dysfunction

Interventions: Biological: octaplas

First Posted Date: 2014-01-31

Last Posted Date: 2020-06-23

Lead Sponsor: Octapharma

Target Recruit Count: 50

Registration Number: NCT02050841

Locations: 🇺🇸
Octapharma Research Site, Saint Louis, Missouri, United States

Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation

Terminated

Conditions: Coagulopathy
Endstage Liver Disease

Interventions: Biological: Octaplas™
Biological: Plasma

First Posted Date: 2014-01-15

Last Posted Date: 2018-03-07

Lead Sponsor: Octapharma

Target Recruit Count: 43

Registration Number: NCT02037373

Locations: 🇺🇸
Octapharma Research Site, Nashville, Tennessee, United States

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Phase 3

Completed

Conditions: Severe Hemophilia A

Interventions: Biological: Human-cl rhFVIII

First Posted Date: 2013-11-25

Last Posted Date: 2021-01-19

Lead Sponsor: Octapharma

Target Recruit Count: 48

Registration Number: NCT01992549

Locations: 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇺🇸
UC Davis Medical Center, Sacramento, California, United States
🇨🇦
McMaster Children's Hospital, Hamilton, Ontario, Canada

and more 12 locations

Octaplas Pediatric Plasma Exchange Trial

Phase 4

Completed

Conditions: Adverse Effects in the Therapeutic Use of Plasma Substitutes

Interventions: Biological: Octaplas™

First Posted Date: 2013-09-10

Last Posted Date: 2020-03-24

Lead Sponsor: Octapharma

Target Recruit Count: 41

Registration Number: NCT01938378

Locations: 🇺🇸
Octapharma Research Site, Cincinnati, Ohio, United States

Octaplas Adult TTP Trial

Terminated

Conditions: Thrombotic Thrombocytopenic Purpura

Interventions: Biological: Octaplas
Drug: Standard Plasma

First Posted Date: 2013-09-10

Last Posted Date: 2019-10-14

Lead Sponsor: Octapharma

Target Recruit Count: 1

Registration Number: NCT01938404

Locations: 🇺🇸
Octapharma Study Site, Rochester, New York, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy